---
document_datetime: 2025-04-25 10:40:09
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/jaypirca-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: jaypirca-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.7950945
conversion_datetime: 2025-12-30 01:37:21.390352
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Jaypirca

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                               |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------|
| II/0002              | Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor for JAYPIRCA, based on interim results from study LOXO-BTK-20020 (BRUIN CLL-321); this is a phase 3 open-label, | 27/02/2025                          | 28/03/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion 'Jaypirca-H-C- 005863/II/0002'. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   | randomized study of LOXO-305 versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated CLL/SLL. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |      |                                   |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| PSUSA/155/2 02407 | Periodic Safety Update EU Single assessment - pirtobrutinib                                                                                                                                                                                                                                                                                                                                                                                                              | 13/02/2025 | n/a        |      | PRAC Recommendation - maintenance |
| IA/0007/G         | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                             | 15/10/2024 | n/a        |      |                                   |
| IB/0005           | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                | 08/10/2024 | 28/03/2025 | SmPC |                                   |
| PSUSA/155/2 02401 | Periodic Safety Update EU Single assessment - pirtobrutinib                                                                                                                                                                                                                                                                                                                                                                                                              | 05/09/2024 | n/a        |      | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| R/0004   | Renewal of the marketing authorisation.                                                                                                                                | 27/06/2024   | 16/08/2024   | SmPC   | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Jaypirca, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0001  | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 07/12/2023   | n/a          |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |